Education
About Us
Working with TipRanks
Follow Us
Medicenna Therapeutics Corp (MDNAF)
OTHER OTC:MDNAF
RESEARCH TOOLSreports
MDNAF Analyst Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MDNAF Stock 12 Month Forecast
Average Price Target
$4.37
▲(561.38%Upside)
| Highest Price Target$6.00 | Average Price Target$4.37 | Lowest Price Target$2.74 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Bloom Burton
$6
Buy
809.09%
Upside
Reiterated
04/29/25
Research Capital
$2.74
Buy
314.75%
Upside
Reiterated
04/28/25
H.C. Wainwright
$2.5
Buy
278.79%
Upside
Reiterated
12/06/24
JonesTrading
$3.65
Buy
453.00%
Upside
Reiterated
12/05/24
We believe the futility hurdle in r/r anal cancer is ORR of >20%. Prior clinical trials evaluating CPIs in anal cancer have shown ORR of 10-14% [S.Rao, J.-P.Spano, et al. ESMO Open. 2022, Vol. 7(4); A. Marabelle, J.-P. Delord, et al. Lancet, 2022, Vol. 7(5); S. Lonardi, F. Pietrantonio, et al. J Immunother Cancer. 2021, Vol. 9(11)].
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Bloom Burton
$6
Buy
809.09%
Upside
Reiterated
04/29/25
Research Capital
$2.74
Buy
314.75%
Upside
Reiterated
04/28/25
H.C. Wainwright
$2.5
Buy
278.79%
Upside
Reiterated
12/06/24
JonesTrading
$3.65
Buy
453.00%
Upside
Reiterated
12/05/24
We believe the futility hurdle in r/r anal cancer is ORR of >20%. Prior clinical trials evaluating CPIs in anal cancer have shown ORR of 10-14% [S.Rao, J.-P.Spano, et al. ESMO Open. 2022, Vol. 7(4); A. Marabelle, J.-P. Delord, et al. Lancet, 2022, Vol. 7(5); S. Lonardi, F. Pietrantonio, et al. J Immunother Cancer. 2021, Vol. 9(11)].
Best Analysts Covering Medicenna Therapeutics Corp
1 Month
xxx
Success Rate
4/8 ratings generated profit
Average Return
+20.20%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +20.20% per trade.
3 Months
xxx
Success Rate
5/8 ratings generated profit
Average Return
+58.24%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +58.24% per trade.
1 Year
Success Rate
6/8 ratings generated profit
Average Return
+204.75%
reiterated a buy rating 2 months ago
Copying Andre Uddin's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +204.75% per trade.
2 Years
xxx
Success Rate
6/9 ratings generated profit
Average Return
+24.19%
reiterated a xxx
rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +24.19% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MDNAF Analyst Recommendation Trends
Rating
Apr 24
Aug 24
Nov 24
Dec 24
Apr 25
Strong Buy
5
3
3
3
5
Buy
1
2
2
2
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
5
5
5
6
Each month's total comprises the sum of three months' worth of ratings.
MDNAF Financial Forecast
MDNAF Stock Forecast FAQ
What is MDNAF’s average 12-month price target, according to analysts?
Based on analyst ratings, Medicenna Therapeutics Corp’s 12-month average price target is 4.37.
What is MDNAF’s upside potential, based on the analysts’ average price target?
Medicenna Therapeutics Corp has 561.38% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MDNAF a Buy, Sell or Hold?
Medicenna Therapeutics Corp has a consensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
What is Medicenna Therapeutics Corp’s price target?
The average price target for Medicenna Therapeutics Corp is 4.37. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $6.00 ,the lowest forecast is $2.74. The average price target represents 561.38% Increase from the current price of $0.66.
The highest analyst price target is $6.00 ,the lowest forecast is $2.74. The average price target represents 561.38% Increase from the current price of $0.66.
What do analysts say about Medicenna Therapeutics Corp?
Medicenna Therapeutics Corp’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
How can I buy shares of MDNAF?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.